KRAS is a gene that can mutate and become a driver of cancer growth in many types of cancer. Treating KRAS-mutated cancers is challenging, but there are several approaches doctors are using and developing:
Targeted Therapies
- Sotorasib (Lumakras): This is the first FDA-approved drug specifically targeting KRAS mutations. It works by inhibiting the activity of the mutated KRAS protein.
- Adagrasib (MRTX849): Another FDA-approved drug targeting KRAS mutations. It works similarly to sotorasib.
- Other Therapies: Researchers are actively developing other targeted therapies that specifically target KRAS mutations or the pathways involved in cancer growth driven by KRAS.
Combination Therapies
- Combining Targeted Therapies with Other Treatments: Doctors are investigating using targeted KRAS therapies in combination with other treatments such as chemotherapy, immunotherapy, and radiation therapy.
Immunotherapy
- Boosting the Immune System: Researchers are exploring ways to use immunotherapy to help the body's immune system fight KRAS-mutated cancers.
Ongoing Research
- New Therapies: Scientists are constantly researching new ways to treat KRAS-mutated cancers, including developing new drugs, vaccines, and other therapies.
It is important to note that treatment options for KRAS-mutated cancers vary depending on the specific type of cancer, the stage of the cancer, and the patient's overall health.
